TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients

BMC Cancer

Table 4 Correlations between serum concentration of CA-125, TIMP-1 and VEGF and clinicopathological factors

	Age		Residual Tumor		Ascites		pN		Grading
	p-value	+/-	p-value	+/-	p-value	+/-	p-value	+/-	p-value	+/-
CA-125 before surgery	0.046	+	0.631	.	0.004	+	0.254*		0.121*
CA-125 before CTX	0.169	.	0.619	.	0.619	.	1.000*		0.118*
CA-125 during CTX	0.238	.	0.533	.	0.774	.	0.440*		1.000*
CA-125 after CTX	0.300	.	0.948	.	0.275	.	0.339*		0.238*
TIMP-1 before surgery	0.273	.	0.812	.	0.096	.	0.423*		0.682*
TIMP-1 before CTX	0.387	.	0.169	.	0.430	.	0.414*		1.000*
TIMP-1 during CTX	0.229	.	0.934	.	0.201	.	0.257*		0.429*
TIMP-1 after CTX	0.086	.	0.157*	.	0.032*	+	0.218*		0.688*
VEGF before surgery	0.273	.	0.597	.	0.550	.	1.000*		0.08*
VEGF before CTX	0.221	.	0.280	.	0.946	.	0.226*		1.000*
VEGF during CTX	0.395	.	0.724	.	0.486	.	1.000		0.688*
VEGF after CTX	0.303	.	0.829	.	0.829	.	0.110*		0.688*

Correlations between serum concentration of CA-125, TIMP-1 and VEGF (below/above median) and clinicopathological factors. A positive correlation indicates a higher likelihood of an event. P-values from the Pearson-Chi²-Test and from Fisher's exact test (*) are reported for binary correlations with age: <61 years versus 61 years or older; ascites: <500 ml versus >500 ml; residual tumor after surgery: microscopic versus macroscopic; lymph node status: no metastasis versus lymph-node metastasis; grading: G2 versus G3. +/- indicates the direction of a significant correlation.

ISSN: 1471-2407